Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.
Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an
As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n
Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl